Cadila Healthcare says Changodar plant has got no USFDA observation

Ahmedabad-based pharma major Cadila Healthcare on Friday informed the stock exchanges that no observations were issued by the US Food and Drugs Administration (FDA) against its topicals manufacturing plant at Changodar.

The plant was inspected by the US FDA between April 3 and April 7. According to a notice to the BSE, no observation (483) was issued. The company has filed 17 products with the US FDA from the site. Shares of Cadila Healthcare ended the session, up 1.5 per cent, at ~454.85 a share on the BSE. Earlier, in February, the company's Moraiya unit too did not receive any observations from the US FDA.